Increased risk of hyperkalaemia w/ aliskiren, K salts, K-sparing diuretics, ACE inhibitors, angiotensin-II receptors antagonists, NSAIDs, heparins, immunosuppressant agents eg, ciclosporin, tacrolimus, trimethoprim, co-trimoxazole. Increased risk of hyperkalaemia, worsened renal function, CV morbidity & mortality w/ aliskiren. Increased risk of severe anaphylactoid reactions w/ extracorporeal treatments eg, dialysis or haemofiltration. Increased risk of angioedema w/ sacubitril/valsartan, estramustine, racecadotril, mTOR inhibitors eg, sirolimus, everolimus, temsirolimus; gliptins eg, linagliptin, saxagliptin, sitagliptin, vildagliptin. Reduced heart rate & cardiac output & vasodilation w/ centrally-acting antihypertensives eg, clonidine, methyldopa, moxonidine, rilmenidine. Potentiated AV conduction time & negative inotropic effect w/ class I antiarrhythmics eg, disopyramide, quinidine, lidocaine, phenytoin, flecainide, propafenone. Negative influence on contractility & AV conduction w/ verapamil- & diltiazem-type Ca antagonists. Additive hyperkalaemic effects w/ K-sparing diuretics eg, triamterene, amiloride; K-salts. Reversible increased serum conc & toxicity of lithium. Increased blood-glucose lowering effects w/ antidiabetics eg, insulin, oral hypoglycemics. Attenuated antihypertensive effects w/ NSAIDs eg, acetylsalicylic acid, COX-2 inhibitors & non-selective NSAIDs. Increased hypotensive effects w/ antihypertensive agents, vasodilators. Reduced BP w/ anaesth medicinal products, TCAs, antipsychotics. Reduced reflex tachycardia & increased risk of hypotension w/ anaesth. Reduced effects w/ β- & α-sympathomimetics. Increased risk of hypotension & ventricular pump function deterioration w/ dihydropyridine-type Ca antagonists eg, felodipine, amlodipine. Potentiated AV conduction time w/ class III antiarrhythmic drugs eg, amiodarone. Increased AV conduction time & risk of bradycardia w/ parasympathomimetic drugs. Additive systemic effects w/ topical β-blockers. Reduced heart rate & increased AV conduction time w/ digitalis glycosides. Increased antihypertensive effects w/ baclofen. Excessive BP reduction w/ non-K-sparing diuretics. Increased risk of bradycardia w/ mefloquine. Enhanced hypotensive effects w/ MAOIs (except MAO-B inhibitors). Nitritoid reactions w/ injectable gold (Na aurothiomalate).